Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG Logo
Lonza Group AG
SIX:LONN
Watchlist
Price: 521.4 CHF -0.04% Market Closed
Market Cap: 35.9B CHF
Have any thoughts about
Lonza Group AG?
Write Note

Operating Margin
Lonza Group AG

13.1%
Current
18%
Average
2.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.1%
=
Operating Profit
874m
/
Revenue
6.7B

Operating Margin Across Competitors

Country CH
Market Cap 37.6B CHF
Operating Margin
13%
Country US
Market Cap 1.3T USD
Operating Margin
14%
Country US
Market Cap 196.3B USD
Operating Margin
17%
Country US
Market Cap 170.3B USD
Operating Margin
21%
Country KR
Market Cap 66.5T KRW
Operating Margin
31%
Country US
Market Cap 38.5B USD
Operating Margin
25%
Country US
Market Cap 36.7B USD
Operating Margin
14%
Country US
Market Cap 26.4B USD
Operating Margin
28%
Country US
Market Cap 23B USD
Operating Margin
20%
Country US
Market Cap 22.3B USD
Operating Margin
8%
Country US
Market Cap 22.2B USD
Operating Margin
29%
No Stocks Found

Lonza Group AG
Glance View

Market Cap
37.6B CHF
Industry
Life Sciences Tools & Services

Lonza Group AG is a Swiss multinational company that specializes in the life sciences and advanced materials industries, making it an integral player in the global biotechnology and pharmaceutical landscapes. Founded in 1897, Lonza has evolved from a traditional chemical manufacturer to a leading contract development and manufacturing organization (CDMO) that partners with clients to accelerate the development of innovative therapies. The company offers a wide range of services, including biopharmaceutical manufacturing, cell and gene therapy solutions, and specialized expertise in microbial products and industrial bioprocessing. As pharmaceutical companies continue to explore complex biologics, Lonza stands out for its extensive technological capabilities and state-of-the-art facilities, positioning itself at the forefront of an industry that is rapidly transforming healthcare. For investors seeking to understand Lonza's value proposition, it’s essential to appreciate the company's robust financial performance and strategic growth initiatives. Lonza has consistently demonstrated strong revenue growth, driven by its diversified portfolio and a commitment to research and development. The company has made significant investments in expanding its global manufacturing footprint, notably through the integration of advanced technology for efficient production processes. Furthermore, Lonza's strategic collaborations with major pharmaceutical enterprises in cell and gene therapies highlight its potential for sustained growth. As the world increasingly emphasizes innovation in the healthcare sector, Lonza Group AG remains well-poised to capitalize on emerging opportunities, making it an attractive prospect for investors looking to tap into the growing life sciences market.

LONN Intrinsic Value
613.89 CHF
Undervaluation 15%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.1%
=
Operating Profit
874m
/
Revenue
6.7B
What is the Operating Margin of Lonza Group AG?

Based on Lonza Group AG's most recent financial statements, the company has Operating Margin of 13.1%.